-Tehelka The NDA government’s move to open more Jan Aushadhi stores ignores the multitude of issues currently plaguing them Amidst the jostling crowd at the Guru Teg Bahadur Hospital in Shahdara, Delhi, is 68-year-old Suresh Chandra, holding his medical files on one hand and prescription letter on the other. Chandra, who is a lung disease patient, moves towards the Jan Aushadhi store, situated in the hospital premises. Chandra hopes that the government-run medical...

-The Times of India MUMBAI: Faced with complaints of overpricing of medical devices like cardiac stents and implants, the government seems to be finally getting its act together. According to a government official, in a string of measures to regulate the industry under the Draft National Medical Device Policy, it has recommended creating an autonomous body — the National Medical Devices Authority (NDMA) — pricing control for medical devices by including them...

-The Times of India NEW DELHI: The drug price regulator has capped prices of 30 medicines including antibiotics and those used in treatment of diabetes, tuberculosis and malaria. The move is expected to bring down prices of most of these medicines by 25-30%. However, in some cases the reduction could be by as much as 50%. The National Pharmaceutical Pricing Authority (NPPA), which has the mandate to regulate prices of essential medicines,...

-Economic and Political Weekly The key to improving the quality of healthcare services in India and reducing costs at the same time can be found by enacting legislation which lays down minimum standards of patient care. In the absence of such standards and the reluctance of health insurance companies to standardise either price or quality, healthcare services continue to be expensive and of doubtful quality. Developing standards of patient care by...

-Business Standard This would be in addition to 348 drugs already under price ceiling The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of another 52 essential drugs, in a move that could impact drug manufacturers Lupin, Cadila Healthcare and Merck. This is in addition to the 348 drugs already under a price ceiling. The majority of the 52 new drugs are antibiotics, painkillers and medicines used for treating cancer and skin...